Menlo Park, United States
Satoris Inc. is a pioneering force in the realm of Biotechnology with a specific focus on the Health Care segment. Founded in 2003, this privately held company is headquartered in the United States and is dedicated to advancing diagnostic technologies for molecular profiling of neurological disorders, prominently targeting Alzheimer's disease (AD).
Utilizing a landmark study on the classification and prediction of clinical AD diagnostics published in Nature Medicine, Satoris is developing tests founded on plasma signaling proteins. This promising technological approach appears poised to revolutionize early diagnostic measures, potentially impacting over 26 million global AD cases. By integrating proprietary decision-based algorithms and bioinformatics tools, Satoris aims to cut healthcare costs through efficient patient management.
The company secured a $5.20M Series B investment in March 2008, supported by backers like Life Science Angels and Brain Trust Accelerator Fund. As it ventures into new markets for neurological diagnostics, Satoris represents a compelling investment opportunity with significant growth potential.
-logo.jpg "Diagnostics Biochem Canada (DBC)"){kind=logo}
